Sugi Predict

Sugi Predict / Targets / PIK3R3

PIK3R3

Phosphatidylinositol 3-kinase regulatory subunit gamma · Q92569 · PIK3R3 on Sugi Atlas →

4,744 patent compounds predicted against PIK3R3, 2,306 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7050 SCHEMBL7050 1.00 20/20
SCHEMBL7052 SCHEMBL7052 1.00 20/20
SCHEMBL7070 SCHEMBL7070 1.00 20/20
SCHEMBL7166 SCHEMBL7166 1.00 20/20
SCHEMBL7186 SCHEMBL7186 1.00 20/20
SCHEMBL7257 SCHEMBL7257 1.00 20/20
SCHEMBL7283 SCHEMBL7283 1.00 20/20
SCHEMBL7291 SCHEMBL7291 1.00 20/20
SCHEMBL7499 SCHEMBL7499 1.00 20/20
SCHEMBL7530 SCHEMBL7530 1.00 20/20
SCHEMBL7558 SCHEMBL7558 1.00 20/20
SCHEMBL7575 SCHEMBL7575 1.00 20/20
SCHEMBL7603 SCHEMBL7603 1.00 20/20
SCHEMBL7607 SCHEMBL7607 1.00 20/20
SCHEMBL7619 SCHEMBL7619 1.00 20/20
SCHEMBL7633 SCHEMBL7633 1.00 20/20
SCHEMBL7659 SCHEMBL7659 1.00 20/20
SCHEMBL7693 SCHEMBL7693 1.00 20/20
SCHEMBL7700 SCHEMBL7700 1.00 20/20
SCHEMBL7728 SCHEMBL7728 1.00 20/20

Clinical trials — most relevant to PIK3R3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway PHASE4COMPLETED
Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations PHASE3COMPLETED
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) PHASE2ACTIVE_NOT_RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia PHASE2WITHDRAWN
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) PHASE2ACTIVE_NOT_RECRUITING
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss PHASE2RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Can Dormant Perimenopausal Ovarian Follicles Become FSH Responsive? nanUNKNOWN
Exploring the Link Between Cancer Genetics and PPSP nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PIK3R3 binder may also engage these)

ProteinNameSimilarity
O46404 — 0.997 O46404 →
Q63789 — 0.996 Q63789 →
Q64143 — 0.993 Q64143 →
P26450 — 0.951 P26450 →
PIK3R1 Phosphatidylinositol 3-kinase regulatory subunit alpha 0.949 landscape →
Q61187 — 0.945 Q61187 →
Q5R685 — 0.943 Q5R685 →
Q63787 — 0.943 Q63787 →
Q9TUZ1 — 0.942 Q9TUZ1 →
P60762 — 0.942 P60762 →
P23727 — 0.941 P23727 →
Q9ERA0 — 0.941 Q9ERA0 →
Q9TUM3 — 0.941 Q9TUM3 →
MORF4L1 Mortality factor 4-like protein 1 0.940 landscape →
P42232 — 0.940 P42232 →
Q6IRE4 — 0.940 Q6IRE4 →
Q9TUZ0 — 0.940 Q9TUZ0 →
P42230 — 0.940 P42230 →
STAT5B Signal transducer and activator of transcription 5B 0.939 landscape →
P52632 — 0.939 P52632 →
Q6NZH6 — 0.938 Q6NZH6 →
STAT5A Signal transducer and activator of transcription 5A 0.937 landscape →
A2A432 — 0.937 A2A432 →
Q5PYH5 — 0.937 Q5PYH5 →
Q8AVU2 — 0.936 Q8AVU2 →
Q62771 — 0.936 Q62771 →
Q95115 — 0.935 Q95115 →
Q12800 — 0.935 Q12800 →
Q4V860 — 0.935 Q4V860 →
Q8BUL6 — 0.935 Q8BUL6 →